Inhaled treprostinil for exercise-induced pulmonary hypertension
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with exercise-induced pulmonary hypertension based on a specific heart-lung exercise test.
- You experience shortness of breath when exercising.
- You can perform exercise testing on a bike or treadmill.
- If you can become pregnant, you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests if special breathing exercises can help people with pulmonary hypertension. You may join if your condition is stable and you haven't smoked in the last 10 years.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.